Piper Sandler Maintains Neutral on IDEXX Laboratories, Lowers Price Target to $520
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Westenberg maintains a Neutral rating on IDEXX Laboratories (NASDAQ:IDXX) and lowers the price target from $600 to $520.
August 14, 2024 | 3:58 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Piper Sandler maintains a Neutral rating on IDEXX Laboratories and lowers the price target from $600 to $520.
The lowered price target from $600 to $520 by Piper Sandler suggests a less optimistic outlook for IDEXX Laboratories, which could negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100